Active, not recruitingPhase 2NCT06054113
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Studying Precursor B-cell acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amgen
- Principal Investigator
- MD, MDAmgen
- Intervention
- Blinatumomab(drug)
- Enrollment
- 18 target
- Eligibility
- All sexes
- Timeline
- 2024 – 2027
Study locations (7)
- The Second Hospital of Anhui Medical University, Hefei, Anhui, China
- Childrens Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
- Wuhan Childrens Hospital, Wuhan, Hubei, China
- Children's Hospital of Soochow University, Suzhou, Jiangsu, China
- Shanghai Children's Medical Center, Shanghai, Shanghai Municipality, China
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06054113 on ClinicalTrials.govOther trials for Precursor B-cell acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07470073A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and AdultsUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNANCT07371403MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic LeukemiaKing Hussein Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07575971Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic LeukemiaLiping Dou
- RECRUITINGPHASE3NCT07441291CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCTPeking University People's Hospital
- ACTIVE NOT RECRUITINGNCT07269587A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19Ruijin Hospital
- RECRUITINGPHASE1NCT07066397A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALLTriArm Therapeutics (Taiwan) Limited
- RECRUITINGPHASE2NCT06985485Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline ChemotherapyThe First Affiliated Hospital of Soochow University
- RECRUITINGNANCT07003737Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell TransplantationFirst Affiliated Hospital of Zhejiang University
See all trials for Precursor B-cell acute lymphoblastic leukemia →